U.S. FDA approves Pfizer drug for menopause symptoms

Reuters

Oct 3 (Reuters) - U.S. health regulators approved PfizerInc's menopause drug Duavee, which the company hopeswill reduce hot flashes with fewer side effects than olderhormone-replacement therapies.

The Food and Drug Administration said on Thursday itapproved the drug to treat women with moderate to severemenopause symptoms and to prevent post-menopausal osteoporosis,a bone disease which can increase the risk of fractures.

The drug, which Pfizer is developing with LigandPharmaceuticals Inc, combines bazedoxifene - whichbelongs to a class of drugs known as selective estrogen receptormodulators, or SERMS - and conjugated estrogens, which arederived from the urine of pregnant horses and contained inPfizer's menopause drug Premarin.

View Comments (0)